ArticleThe ISME journal2025
Complete xylan utilization pathway and regulation mechanisms involved in marine algae degradation by cosmopolitan marine and human gut microbiota.
Article in The ISME journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glucose Modulates Marine Xylanase Activity: Insights From Caulerpa lentillifera and Synthetic β-1,3-glucoxylans.Chembiochem : a European journal of chemical biology · 2026Article
- Automated Syntheses of Xylan Oligosaccharides Containing β3-Linkages Enable Substrate Specificity Studies of Xylanases from Marine Bacteria.Organic letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-1,3-xylan, typically found in marine algae as a major cell wall polysaccharide, represents an overlooked pool of organic carbon in global oceans. Whilst our understanding of microbial catabolism of xylans has improved significantly, particularly from biotransformations of terrestrial plant biomass that are typically composed of β-1,4-xylans, knowledge on how microbes utilize β-1,3-xylan remains limited. Here, we describe the discovery of a complete pathway for β-1,3-xylan catabolism and its regulation in a marine bacterium, Vibrio sp. EA2. The pathway starts with the extracellular decomposition of β-1,3-xylan by two β-1,3-xylanases into β-1,3-xylooligomers, which are mainly internalized by an ATP-binding cassette transporter. The substrate binding protein of this transporter has an L-shaped substrate binding pocket to preferentially bind β-1,3-xylooligomers. Subsequently, two intracellular β-1,3-xylosidases degrade β-1,3-xylooligomers into fermentable xylose. The pathway is activated by a unique regulator with xylose being the effector. This β-1,3-xylan catabolic pathway differs from that of β-1,4-xylan catabolism in enzymes, transporters, and regulators. Bioinformatic analysis suggests that the β-1,3-xylan catabolism pathway is not only prevalent in diverse marine bacteria and cosmopolitan human gut microbiota, such as Bacteroides, but also likely transferred horizontally from algae-degrading marine bacteria to the human gut.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.